Peking University - Juntendo University Joint Symposium on Cancer Research and Treatment

Kan Gong, Pengjie Wu, X. L. Wang, Xianghui Ning, Teng Li, Shuanghe Peng, Jiangyi Wang, Jinchao ChenJuntendo 2017 · DOI

Abstract

Mutation or inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene is an early event in the pathogenesis of clear cell renal cell carcinomas (RCCs) and is common in both hereditary and nonhereditary forms. This research explores the clinical and molecular landscape of VHL disease within the Chinese population, identifying novel mutations, genetic anticipation, and the critical role of the EPO/EPOR signaling pathway in tumor progression.

Introduction

Renal Cell Carcinoma (RCC) represents a significant global health challenge. While the role of the VHL gene in regulating the hypoxia response is well-documented, clinical data has historically been skewed toward Western cohorts. This study addresses two primary gaps: characterizing the molecular landscape of VHL disease in Chinese patients and identifying actionable downstream therapeutic targets, specifically focusing on the Erythropoietin (EPO) and its receptor (EPOR).

Methods

The researchers conducted a multi-faceted study involving:

  • Clinical Genetics: Analysis of 102 Chinese VHL disease families using PCR-direct sequencing and UPQFM-PCR to identify mutations.
  • Telomere Analysis: Comparison of telomere length between patients and 325 healthy controls to investigate disease onset patterns.
  • Molecular Biology: Utilizing the 786-0 RCC cell line, the team performed siRNA-mediated knockdown of EPOR to assess its impact on cell survival and invasion.
  • In Vivo Validation: Testing the effects of EPOR suppression on tumor growth in nude mouse models.

Key Findings

Genetic Anticipation in Chinese Cohorts

A significant finding was the prevalence of de novo mutations (47.4% of families) and the phenomenon of genetic anticipation. In 31 out of 34 parent-child pairs studied, the child developed the disease at a significantly earlier age than the parent (p < 0.001).

Figure 3: Cumulative incidence of VHL disease onset in parents versus children, demonstrating genetic anticipation.

This earlier onset is linked to telomere dynamics; VHL patients exhibit shorter telomeres than healthy controls, a deficit that appears to compound across generations, potentially accelerating cancer onset.

The EPO/EPOR Pathway as a Therapeutic Target

While EPO is traditionally associated with red blood cell production, this study reveals its role as a potent growth and survival signal in RCC. Knocking down EPOR in RCC cells resulted in a 90% decrease in receptor activation and a 55% reduction in tissue invasion.

Figure 5: Percentage of apoptotic cells following EPOR knockdown via siRNA compared to negative controls.

Crucially, EPOR suppression led to a four-fold increase in apoptosis (programmed cell death), as shown in Figure 5. These results were mirrored in animal models, where EPOR knockdown significantly inhibited tumor volume expansion over a ten-week period compared to controls (p < 0.001).

Discussion and Future Directions

The study highlights the complexity of VHL disease, particularly the challenges posed by mosaic mutations which may be missed by standard screening. While the EPO/EPOR pathway presents a promising therapeutic target, transitioning from siRNA techniques to clinical-grade inhibitors remains a significant hurdle. Future research is needed to elucidate the exact biochemical mechanism by which VHL haplo-insufficiency drives accelerated telomere shortening.

Summary updated

Abstract

Mutation or inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene is an early event in the pathogenesis of clear cell renal cell carcinomas (RCCs) and is common in both hereditary and nonhereditary forms.
BibTeX
@inproceedings{gong2017peking,
  author = {Kan Gong and Pengjie Wu and X. L. Wang and Xianghui Ning and Teng Li and Shuanghe Peng and Jiangyi Wang and Jinchao Chen},
  title = {{Peking University - Juntendo University Joint Symposium on Cancer Research and Treatment}},
  booktitle = {Juntendo},
  year = {2017},
  doi = {10.14789/jmj.63.326},
}
Figure